ZLD1039

Cat. No.: HY-116804

CAS No.: 1826865-46-6

Molecular Formula: $C_{36}H_{48}N_6O_3$

Molecular Weight: 612.8

Target: Histone Methyltransferase

Pathway: Epigenetics

Storage: 4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 9.09 mg/mL (14.83 mM; ultrasonic and adjust pH to 3 with 1M HCl)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.6319 mL	8.1593 mL	16.3185 mL
5 mM	0.3264 mL	1.6319 mL	3.2637 mL
10 mM	0.1632 mL	0.8159 mL	1.6319 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 0.91 mg/mL (1.48 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 0.91 mg/mL (1.48 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

ZLD1039 is a potent, highly selective, and orally bioavailable EZH2 inhibitor. ZLD1039 shows potent and concentration-dependent inhibition of PRC2 enzymatic activity against EZH2 wild-type as well as Y641F, and A677G mutant enzymes with IC_{50} values of 5.6, 15, and 4.0 nM, respectively. ZLD1039 inhibits breast tumor growth and metastasis[1].

REFERENCES

[1]. Xuejiao Song, et al. Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer. Sci Rep. 2016; 6: 20864.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA